Nanocarrier-based drug delivery systems: enhancing targeted therapy in oncology

The field of drug delivery has shown promise through Nanocarrier-based drug delivery systems (NDDS) by making targeted cancer therapy more precise with effective drug delivery methods. Therapeutic agents get encapsulated within nanoparticles through these systems, improving bioavailability while permitting controlled release capabilities and tumor cell-specific targeting effects that reduce harm to healthy tissue. Recent developments in NDDS prioritize creating better carrier systems using liposomes, dendrimers, and polymeric nanoparticles to enhance drug accumulation in tumor areas. Therapeutic performance has benefited significantly from implementing targeted mechanisms that use ligand-receptor connections and enhanced permeability and retention (EPR) effect. The research analyzes modern developments of NDDS in the oncology medical field while assessing its transformative influence on future cancer therapy methods. The assessment incorporates extensive clinical trial and experimental study research to evaluate these systems regarding their toxicity-reducing properties and drug-delivery optimization and survival rate enhancements for personalized cancer therapy.